Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Milestone Pharmaceuticals Inc. (MIST)

0.7300 -0.0596 (-7.55%)
At close: October 30 at 4:00:01 PM EDT
0.7372 +0.0072 (+0.99%)
After hours: October 30 at 7:56:54 PM EDT
Trade MIST on Coinbase
Chart Range Bar
Loading chart for MIST

What's happening with MIST?

38m ago
Powered by Yahoo Scout

Milestone Pharmaceuticals is balancing early CARDAMYST commercialization against execution risks and an expanding AFib-RVR clinical program. Analysts lowered fair-value estimates because payer coverage and prescribing adoption remain uncertain, while China’s approval and Phase 3 enrollment broaden the product’s potential reach.

Powered by Yahoo Scout
  • Previous Close 0.7896
  • Open 0.7900
  • Bid 0.7300 x 100
  • Ask 0.8021 x 100
  • Day's Range 0.7259 - 0.7997
  • 52 Week Range 0.6310 - 3.0600
  • Volume 728,347
  • Avg. Volume 1,343,580
  • Market Cap (intraday) 90.884M
  • Beta (5Y Monthly) 1.01
  • PE Ratio (TTM) --
  • EPS (TTM) -0.6800
  • Earnings Date Nov 12, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 5.57
  • Motley Fool Rating Bearish

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.

www.milestonepharma.com

38

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

MIST
63.86%
S&P 500 (^GSPC)
10.73%

1-Year Return

MIST
61.17%
S&P 500 (^GSPC)
11.11%

3-Year Return

MIST
69.33%
S&P 500 (^GSPC)
81.91%

5-Year Return

MIST
87.03%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 559k
Earnings -28.61M
Profit Margin -5,118.78%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-20M
-10M
0
-10000.0%
-8000.0%
-6000.0%
-4000.0%
-2000.0%
0.0%

Analyst Insights

View More

Top Analyst

HC Wainwright & Co.
46/100
Latest Rating
Buy

Analyst Price Targets

1.00
5.57 Average
0.7300 Current
8.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/3/2026
Analyst HC Wainwright & Co.
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 8 -> 8

Statistics

View More

Valuation Measures

Annual
As of 10/29/2026
  • Market Cap

    98.30M

  • Enterprise Value

    -12.24M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    38.49

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    1.76

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -42.78%

  • Return on Equity (ttm)

    -35,522.62%

  • Revenue (ttm)

    2.34M

  • Net Income Avi to Common (ttm)

    -84.01M

  • Diluted EPS (ttm)

    -0.6800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    170.61M

  • Total Debt/Equity (mrq)

    778.53%

  • Levered Free Cash Flow (ttm)

    -41.69M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

0.7300 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: